Are Medical Stocks Lagging Amedisys (AMED) This Year?
Werte in diesem Artikel
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Amedisys (AMED) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Amedisys is one of 997 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Amedisys is currently sporting a Zacks Rank of #2 (Buy).The Zacks Consensus Estimate for AMED's full-year earnings has moved 1.5% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.Based on the most recent data, AMED has returned 3.1% so far this year. At the same time, Medical stocks have lost an average of 6.8%. As we can see, Amedisys is performing better than its sector in the calendar year.BrightSpring Health Services, Inc. (BTSG) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 34.6%.For BrightSpring Health Services, Inc. the consensus EPS estimate for the current year has increased 23.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).Looking more specifically, Amedisys belongs to the Medical - Outpatient and Home Healthcare industry, which includes 17 individual stocks and currently sits at #73 in the Zacks Industry Rank. On average, stocks in this group have gained 2.6% this year, meaning that AMED is performing better in terms of year-to-date returns.BrightSpring Health Services, Inc. however, belongs to the Medical Services industry. Currently, this 58-stock industry is ranked #65. The industry has moved -5.5% so far this year.Investors interested in the Medical sector may want to keep a close eye on Amedisys and BrightSpring Health Services, Inc. as they attempt to continue their solid performance.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.0% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amedisys, Inc. (AMED): Free Stock Analysis Report BrightSpring Health Services, Inc. (BTSG): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Amedisys und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Amedisys
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Amedisys
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Amedisys Inc.
Analysen zu Amedisys Inc.
Datum | Rating | Analyst | |
---|---|---|---|
14.12.2018 | Amedisys Equal Weight | Barclays Capital | |
30.10.2018 | Amedisys Buy | The Benchmark Company | |
19.03.2018 | Amedisys Outperform | RBC Capital Markets | |
09.11.2017 | Amedisys Hold | The Benchmark Company | |
09.11.2017 | Amedisys Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
30.10.2018 | Amedisys Buy | The Benchmark Company | |
19.03.2018 | Amedisys Outperform | RBC Capital Markets | |
08.11.2017 | Amedisys Buy | Mizuho | |
02.11.2017 | Amedisys Buy | The Benchmark Company | |
03.05.2017 | Amedisys Buy | Mizuho |
Datum | Rating | Analyst | |
---|---|---|---|
14.12.2018 | Amedisys Equal Weight | Barclays Capital | |
09.11.2017 | Amedisys Hold | The Benchmark Company | |
09.11.2017 | Amedisys Sector Perform | RBC Capital Markets | |
03.05.2017 | Amedisys Hold | The Benchmark Company | |
01.03.2017 | Amedisys Neutral | Mizuho |
Datum | Rating | Analyst | |
---|---|---|---|
10.01.2012 | Amedisys underperform | Robert W. Baird & Co. Incorporated |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Amedisys Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen